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Introduction: Failure of trophoblast invasion and remodelling of maternal blood vessels leads to the
pregnancy complication pre-eclampsia (PE). In other systems, the sphingolipid, sphingosine-1-
phosphate (S1P), controls cell migration therefore this study determined its effect on extravillous
trophoblast (EVT) function.
Methods: A transwell migration system was used to assess the behaviour of three trophoblast cell lines,
Swan-71, SGHPL-4, and JEG3, and primary human trophoblasts in the presence or absence of S1P, S1P
pathway inhibitors and 1,25(OH)2D3. QPCR and immunolocalisation were used to demonstrate EVT S1P
receptor expression.
Results: EVTs express S1P receptors 1, 2 and 3. S1P inhibited EVT migration. This effect was abolished in
the presence of the specific S1PR2 inhibitor, JTE-013 (p < 0.05 versus S1P alone) whereas treatment with
the S1R1/3 inhibitor, FTY720, had no effect. In other cell types S1PR2 is regulated by vitamin D; here we
found that treatment with 1,25(OH)2D3 for 48 or 72 h reduces S1PR2 (4-fold; <0.05), but not R1 and R3,
expression. Moreover, S1P did not inhibit the migration of cells exposed to 1,25(OH)2D3 (p < 0.05).
Discussion: This study demonstrates that although EVT express three S1P receptor isoforms, S1P pre-
dominantly signals through S1PR2/Ga12/13 to activate Rho and thereby acts as potent inhibitor of EVT
migration. Importantly, expression of S1PR2, and therefore S1P function, can be down-regulated by
vitamin D. Our data suggest that vitamin D deficiency, which is known to be associated with PE, may
contribute to the impaired trophoblast migration that underlies this condition.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Normal placental development depends on the ability of
extravillous trophoblast (EVT) to colonise and transform the spiral
arteries of the maternal uterus into passive conduits that are
capable of supplying the placenta with sufficient oxygen- and
nutrient-rich maternal blood to meet the increasing metabolic
demands of the growing fetus [1]. Abnormalities in EVT function
result in the shallow placental invasion seen in the serious preg-
nancy disease pre-eclampsia (PE) [2]. Options for treating PE are
currently extremely limited [3] so increased understanding of theesearch Centre, University of
ster, M13 9WL, UK.
.uk (E.D. Johnstone).
r Ltd. This is an open access articlemolecular basis of EVT migration and spiral artery remodelling is
needed in the search for medical therapies for this pregnancy
disease.
During normal spiral artery remodelling, EVT reach the vessel
wall by migrating through the lumen or decidual stroma. Oxygen,
cytokines and ECM are known to influence this process [4e6] but
the molecular mechanisms involved in integrating the signals
derived from these environmental cues are unknown. Data from
studies of other vascular beds point to a crucial role for the bioac-
tive sphingolipid metabolite, sphingosine-1-phosphate (S1P)
[7e9]. Moreover, a study using metabolomics to profile placental
tissue in pregnancies complicated by PE [10] identified deranged
sphingolipid metabolism as one of only a handful of pathways
altered in this condition.
S1P activates a family of G-protein coupled receptors (S1PR1-5),under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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different G-proteins allowing for a variety of signalling pathways to
be activated [12]. S1PR1 links exclusively to Gai [13] and can
therefore inhibit adenylate cyclase and the formation of cAMP
[14,15] yet stimulate ERKs and PI3K [16]. S1PR2 couples to Gai, but
also to Gaq, which enables activation of phospholipase C and cal-
cium mobilisation [15], and Ga12/13, which activates Rho and actin
cytoskeleton reassembly (Fig. 1) [17]. S1PR3 activates the same
downstream signalling molecules as S1PR2 [18]. Consequently, the
net cellular response depends on receptor repertoire and S1P can
have stimulatory or inhibitory effects on cell migration depending
on whether S1PR1/3 or S1PR2 is activated [17]. This study aimed to
characterise the S1P receptor repertoire and functional response of
EVT to determine whether deranged S1P signalling could
contribute to abnormal placentation caused by deficient EVT
migration. Following our discovery that S1P inhibited trophoblast
migration in an S1PR2-dependent manner, we identified vitamin D,
known to be deficient in pre-eclampsia [19] as a regulator of S1PR2
and trophoblast function in early placental development.
2. Materials and methods
2.1. Tissue and cell culture
Early first trimester (6e9 week) human placental tissue was
collected following elective surgical or medical termination of
pregnancywithmaternal informed consent and appropriate ethical
review (NREC 08/H1010/28). The human first trimester EVTcell line
Swan-71 [20] was maintained in 1:1 DMEM:Ham's F-12 (Lonza,
Cambridge, UK) supplemented with 10% fetal calf serum (FCS;
Biosera, Maidenhead, UK), penicillin (0.1U/ml), streptomycin
(100 mg/ml) and amphotericin (250 ng/ml; Gibco, Paisley, UK) at
37C, 5% CO2. SGHPL-4 cells [21,22] were cultured in Ham's F-10
(Lonza) with 10% FCS and antibiotic/antimycotic supplements (as
described above) at 37 C, 5% CO2. JEG3 cells (European Collection
of Authenticated Cell Cultures 92120308) were cultured in MEM
with 10% FCS, 1% non-essential amino acids, 2 mM glutamine andFig. 1. S1PR1-3 G-protein linantibiotic/antimycotic supplements at 37C, 5% CO2.
2.2. Immunostaining
Tissue was fixed in 4% paraformaldehyde then embedded in
paraffin and cut into 5 mM sections. These were boiled in 0.01M
sodium citrate buffer, pH 6.0 for antigen retrieval then incubated
with 3% hydrogen peroxide for 10min followed by 5% bovine serum
albumin (BSA) for 30 min. Rabbit non-immune IgG (Dako, Ely, UK),
mouse non-immune IgG (Dako) or primary antibodies (rabbit anti-
S1PR1 (1:50; #sc-25489), anti-S1PR2 (1:100; #sc-25491), S1PR3
(1:100; #sc-30024), all Santa Cruz Biotechnology, or mouse anti-
HLA-G (1:50; #7759, Abcam, Cambridgeshire, UK) were applied
for 2 h at room temperature, then sections were incubated with
biotinylated goat anti-rabbit IgG antibody (1:300; Dako) or goat
anti-mouse IgG antibody (1:300, Dako) for 30 min followed by
avidin peroxidase (5 mg/ml) for 45 min. Immune complexes were
visualised using diaminobenzidine then sections were counter-
stained with Harris's hematoxylin. Sections were observed with an
Olympus BX41 microscope (Olympus, UK;40 objective) and
photographed using a QICAM fast 1364 digital camera (QImaging,
UK). Cells weremethanol-fixed then incubatedwith 0.25% Triton X-
100 for 5 min before blocking (10% donkey serum) for 30 min.
Rabbit or mouse non-immune IgG or primary antibodies (as above)
were applied overnight at 4 C and then cells were incubated for 1 h
at room temperature with an Alexa Fluor 488-conjugated donkey
anti-rabbit IgG (Life Technologies, Paisley, UK) or donkey anti-
mouse IgG (Life Technologies) secondary antibody. Nuclei were
stained with 40,6-diamidino-2-phenylindole (DAPI; Vector, Cam-
bridge, UK). Cells were viewed and imaged using an Olympus IX70
microscope and camera (40 objective).
2.3. EVT cell line migration assay
Cells were seeded into transwell filters (8 mM pores; BD Bio-
sciences) and incubated for 24 h in media (as above except FCS was
reduced to 1%) containing 0.1e10 mM S1P (Sigma-Aldrich, Poole,ked signalling cascades.
Table 1
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the upper surface of the membrane were removed using a cotton
swab and the remainder were stained with Harris's hematoxylin
(Sigma). Cells were viewed by light microscopy (Olympus BX41
microscope,10 magnification); the number of cells in 6 fields of
view were counted. In some experiments, the S1PR-1/3 inhibitor,
FTY720 or pFTY720 (100 nM, Cayman Chemical Company, Ann
Arbor, USA), the S1PR2 inhibitor, JTE-013 (100 nM, Tocris, Abing-
don, UK) or the Rho kinase inhibitor, Y27632 (10 mM; Cytoskeleton
Inc., USA) was added to cultures for 30 min before treatment with
100 nM S1P for a further 24 h. In experiments to assess the affect of
1,25-dihydroxyvitamin D (D3; Sigma) on EVT migration, D3 (1-
10 nM) was added for 48 h or 72 h before incubation with 100 nM
S1P for a further 24 h.
2.4. Primary EVT migration assay
Terminal portions of villi from first trimester placentas were
seeded onto collagen gels and cultured overnight in a 1:1 mix of
DMEM and Ham's F12 containing L-glutamine (2 mmol/L), peni-
cillin (100 IU/ml), and streptomycin (100 mg/ml) at 37 C in a hu-
midified incubator (5% CO2). Those that had attached (radial stress
lines in the collagen gel) and showed evidence of functioning
extravillous trophoblast (presence of cell outgrowth from the
explant border) were selected for further experimentation and
imaged (using a Nikon Eclipse TE 200 inverted microscope and a
Nikon Coolpix 990 digital camera (Nikon, Tokyo, Japan)) at this time
point (deemed 0 h) explants were then cultured with S1P (100 nM)
or fetal calf serum (control) for 24 h before reimaging allowing
changes in outgrowth and migration to be assessed.
2.5. cAMP analysis
Swan-71 cells were stimulated with forskolin (5 mM; Sigma) in
the absence or presence of an S1PR1/3 (100 nM) and/or R2 inhibitor
(100 nM) for 30 min before the addition of S1P (100 nM) or vehicle
for 30 min. Levels of cAMP were determined using the cAMP-Glo
assay in accordance with the manufacturer's instructions (Prom-
ega, Southampton, UK).
2.6. Western blotting
Lysates of Swan-71 cells were prepared in RIPA buffer and 50 mg
protein from each sample was resolved by SDS-PAGE and trans-
ferred to nitrocellulose membranes for Western blotting with a
rabbit antibody specific for phosphorylated Akt (1:1000; #9271,
Cell-Signalling Technology). Immune complexes were visualised by
probing membranes with a HRP-conjugated anti-rabbit IgG anti-
body (1:2000; Dako) followed by chemiluminescence reagents and
exposure to X-ray film. Membranes were stripped (2% SDS, 100 mM
b-mercaptoethanol, 50 mM Tris, pH 6.8, for 30min at 50 C) and re-
probed with an antibody that recognises total Akt (1:1000; #4685,
Cell Signalling Technology) in order to confirm equal protein
loading.
2.7. Analysis of the actin cytoskeleton
Swan-71 cells were treated with vehicle, S1P (100 nM), or S1P
and the Rho kinase inhibitor (Y-27632; 10 mM) for 30min then fixed
in 4% formaldehyde, 1% triton for 5 min. After washing, cells were
stained using Alexa Fluor 594-conjugated phalloidin (150 nM; Life
Technologies, UK) in 1% BSA for 40 min; nuclei were stained with
DAPI. Cells were observed and photographed using an Axio
Observer.Z1 microscope (Carl Zeiss Ltd, UK;40 objective) and an
Axiocam MR microscope camera (Carl Zeiss).2.8. Rac activity assay
The effect of S1P on the activity of Rac in Swan-71 cells was
analysed using the G-LISA Rac Activation BiochemKit in accordance
with the manufacturer's instructions (Cytoskeleton, Inc, USA).
Briefly, Swan-71 cells were cultured in the absence or presence of
100 nm S1P or 100 ng/ml EGF (as a positive control) for 60 s, lysed
and then the level of active Rac in 0.5 mg/ml protein from each
sample was determined using an antibody to capture GTP-bound
Rac followed sequentially, by a Rac specific antibody, a HRP-
labelled antibody, HRP detection reagent and finally, measure-
ment of absorbance at 490 nM.
2.9. QPCR
Total RNA; Absolutely RNA microprep kit (Stratagene, USA),
reversed transcribed using an Affinity Script Multi Temperature Kit
(Stratagene). QPCR was conducted using Brilliant SYBR Green qPCR
Master Mix (Stratagene), 5-carboxy-x-rhodamine reference dye
and specific primers (200 nM; Invitrogen) for S1PR1-3, VDR and the
housekeeping gene, YWHAZ (Table 1) in a Stratagene Mx3000P Real
Time PCR machine. mRNA levels were quantified against standard
curves generated from human reference total RNA.
2.10. Statistical analysis
Data are presented as mean ± standard error of the mean (SEM)
ormedian. Datawere analysed using a one-way analysis of variance
(Kruskal-Wallis with Dunn's post-hoc test) or Wilcoxon signed-
rank test; P < 0.05 was considered significant. Statistical analyses
were performed using Graph Pad Prism (6.0).
3. Results
3.1. EVT express S1P receptors 1-3
Immunohistochemical analysis revealed that in primary tissue,
the migratory trophoblast in villous cell columns (identified by
staining for HLA-G in serial sections) express S1PR1, R2 and R3,
though predominantly R1 and R2 (Fig. 2A). All three receptors were
expressed by syncytio- and cytotrophoblast and also cells in the
stroma. S1PR1-3 protein was also detected in the EVT cell lines,
Swan-71 (Fig. 2B) and SGHPL-4 cells (Fig. 2C).
3.2. S1P attenuates EVT migration via S1PR2
S1P had no affect on the proliferation or viability of the EVT cell
lines (data not shown) however, migration was significantly
attenuated following exposure to S1P. 100 nM S1P was sufficient to
Fig. 2. Expression of S1P receptors in primary extravillous trophoblast (EVT) and EVT cell lines. S1PR protein localisation was determined by immunostaining of human first
trimester placenta (A), Swan-71 cells (B) and SGHPL-4 cells (C) counterstained with hematoxylin or DAPI. Staining for HLA-G was used to indicate extravillous trophoblast and some
slides were incubated with IgG instead of primary antibody as a negative control. Bar represents 20 mM. Images are representative of 4 independent experiments.
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migration (Fig. 3A). This dose had a similar effect on the motility of
SGHPL-4 cells (Fig. 3D) and choriocarcinoma-derived JEG3 cells
(Fig. 3E), which are recommended for use in studies of cell motility
[23] (24 (±2.1)% and 40 (±5.5)% versus control respectively;
p < 0.05). Incubation of human first trimester placental explants
with 100 nM S1P also inhibited the migration of EVT (Fig. 3B),
therefore all subsequent experiments were conducted using
100 nM S1P.
As trophoblast cells express three of the S1P receptor isoforms,
we used inhibitors specific for R1/3 (FTY720 and pFTY720) and R2
(JTE-013) to determine which receptor was responsible for medi-
ating S1P's effect on migration. Fig. 3C-E demonstrates that pre-
treatment of Swan-71 (Fig. 3C), SGHPL-4 (Fig. 3D) and JEG3
(Fig. 3E) cells with JTE-013, but not FTY720 or pFTY720 abolished
S1P's ability to inhibit migration, suggesting that S1P is signalling
through S1PR2.
We next investigatedwhether S1PR1, the other receptor isoform
predominantly expressed by primary EVT, is active in Swan-71 cells
by examining the effect of S1P on cAMP production. Forskolin-
stimulated cAMP production was inhibited by S1P (Fig. 4A) and
importantly, this effect was prevented by inhibiting S1PR1 and not
R2 activity, suggesting that S1P inhibition of adenylate cyclase ac-
tivity is mediated via S1PR1/Gai coupling (Fig. 4A). Further evi-
dence for the ability of S1P to activate Gai was sought byinvestigating the activation status of the signalling molecule, Akt,
which is known to be downstream of this G-protein [24]. We were
also interested in determining whether activation of Gai/Akt was
S1P dose dependent as previous studies have suggested that this
pathway might dominate at lower doses. Fig. 4B shows that S1P is
capable of activating Akt and, importantly, that activation was
apparent at all of the S1P doses used, confirming that S1P signalling
through Gai is possible in EVT. Together, these data suggest that
S1P/S1PR2 binding causes preferential activation of the Ga12/13/
Rho/ROCK pathway rather than Gai/Rac signalling, which is
consistent with S1P's inhibitory affect on the migration of these
cells. Indeed pre-treatment of Swan-71 cells with the ROCK in-
hibitor, Y27632, attenuated S1P-induced stress fibre formation
(Fig. 5A) and S1P-inhibition of migration (Fig. 5B). Furthermore,
treatment of Swan-71 cells with 100 nM S1P for 60 s caused a 50%
decrease in activity (p < 0.05) of the pro-migratory GTPase, Rac
(Fig. 5C).
3.3. S1P's inhibitory actions can be attenuated by vitamin D
The data described above suggest that reducing the expression
of S1PR2 might attenuate S1P's inhibitory affect on EVT cell
migration. We therefore investigated the effect of vitamin D on
S1PR2 expression and the migratory ability of EVT as a study by
Kikuta et al. demonstrated that vitamin D reduced S1PR2
Fig. 3. S1P attenuates EVT migration via S1PR2. (A) Swan-71 cells were seeded on cell culture transwell inserts, incubated for 24 h with varying concentrations of S1P (100nM-
10mM) or vehicle control (methanol) and then the number of cells that had migrated through the filter (8 mM pores) was determined by counting the number of cells present in
micrographs taken, using an Olympus inverted microscope at 10 magnification, of six different fields for each insert. Data are presented as percentage of cells, relative to control,
that had migrated. Bar emean ± SEM; x - p < 0.05; n ¼ 5. (B) Primary placental villous tips were embedded in collagen, cultured for 24 h and then photographed (baseline). Tissue
was treated with media containing either 1% fetal calf serum (control), 100 nM S1P or 100 nM S1P and 100 nM JTE013 for a further 24 h before photographing the same area of
explant. The images shown are representative of those obtained from four independent experiments. Swan-71 cells (C), SGHPL-4 cells (D) or JEG3 cells (E) were incubated with
100 nM of S1PR1/3 inhibitor, FTY720 (C-D) or FTY720p (E) or the S1PR2 inhibitor, JTE-013 (100 nM; C-E) for 30 min before the addition of vehicle or S1P (100 nM) and culture for
24 h. The number of cells that had migrated through the filter is shown as percentage relative to untreated cells. Bar e mean ± SEM; x - p < 0.05 versus untreated cells; n ¼ 7.
Fig. 4. S1PR1 is active in EVT cells. (A) Swan-71 cells were cultured in the absence or presence of forskolin (1 mM) for 15 min. The S1PR2 inhibitor JTE-013 (100 nM), the S1P R1/3
inhibitor FTY720 (100 nM) or vehicle was added for 20 min then cells were cultured in the absence or presence of 100 nM S1P for a further 30 min before measuring intracellular
cAMP levels. Data are from four independent experiments and are expressed relative to control. Bar emean ± SEM; x - p < 0.05 versus untreated cells; $ - p < 0.05 versus forskolin
treatment alone; # - p < 0.05 versus forskolin and S1P treatment. (B) Swan-71 cells were exposed to S1P (0-100 nM) for 10 min or 1 h then cell lysates were analysed by western
blotting using antibodies that recognise phosphorylated (pAkT) or total Akt. Blots are representative of data obtained from 3 independent experiments.
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in vivo, with a consequent increase in themigration of cells towards
S1P [25]. We first confirmed that the trophoblast cell lines express
the vitamin D receptor (data not shown) then cells were incubated
with 1 or 10 nM of 1,25-dihydroxyvitamin D (D3) for either 48 h or
72 h. qPCR analysis revealed a significant reduction in the expres-
sion of S1PR2 mRNA following treatment with 10 nM D3 for either
time period (Fig. 6A). Importantly, pre-treating cells with 10 nM D3
for 48 h or 72 h reversed the inhibitory effect of S1P on trophoblast
cell migration (Fig. 6B).4. Discussion
Although S1P is well known as a regulator of cellular motility
[26], this is the first study to examine the effects of this bioactive
lipid on the behaviour of human EVT.
Extracellular S1P functions through its receptors, S1PR1e5 and
in this study we demonstrated the presence of S1PR1-3 on primary
EVT cells and in our trophoblast models. Previous studies of other
cell types have indicated that the effect of S1P on migration and
invasion depends onwhich S1P receptor(s) are activated. We found
Fig. 5. S1P activates RhoA/ROCK but inhibits Rac. Swan-71 cells were treated with vehicle (control), S1P (100 nM) or the Rho kinase inhibitor Y-27632 (10 mM) for 30 min followed
by S1P (100 nM) for a further 30 min or 24 h before staining with Alexa Fluor 594-conjugated phalloidin and DAPI (A) or assessing migration (B) respectively. Bar e mean ± SEM;
n ¼ 6; x - p < 0.05 relative to culture in the absence of S1P. (C) Swan-71 cells were cultured in the absence (control) or presence of S1P (100 nM) or a known stimulator of cAMP
synthesis, EGF (100 ng/ml), for 60 s, lysed and then the level of active Rac in 0.5 mg/ml protein from each sample was determined using the G-LISA Rac Activation Biochem Kit. Bar e
mean ± SEM; n ¼ 5; x - p < 0.05 relative to control.
Fig. 6. Vitamin D suppresses S1PR2 expression and attenuates S1P-mediated inhibition of EVT cell migration. Swan-71 cells were incubated with vehicle or 1-10 nM 1,25-
dihydroxyvitamin D (D3) for 48 or 72 h then (A) the level of S1PR2 mRNA, normalised to the housekeeping gene YWHAZ, was measured by qPCR (n ¼ 3). (B) Swan-71, SGHPL-
4 or JEG3 cells were cultured in 10 nM D3 for 48 h then seeded in transwells and incubated in the absence or presence of 100 nM S1P for a further 24 h before assessing migration
(n ¼ 5-7). Bar e median; x - p < 0.05 versus cells cultured in the relevant control medium (absence or presence of D3), normalised to 100%.
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[27]), inhibited migration in our three EVT models, suggesting
preferential activation of S1PR2. A previous study using the cell line
HTR8/SVneo found that S1P promoted trophoblast cell migration
[28], though these authors employed a lower concentration of S1P
(10 nM) and it is possible that these cells, which are reported tohave fewer transcripts in commonwith primary EVT than JEG3 cells
[23], predominantly express S1PR1/3. Furthermore, it has recently
been demonstrated that the HTR8/SVneo cell line contains a mixed
population of different cell types, which may have resulted in non-
EVT specific responses to S1P [29]. In order to substantiate the
notion that S1PR2 is involved in inhibiting the migration of the
M. Westwood et al. / Placenta 60 (2017) 1e8 7trophoblast cell lines utilised on the current study, we tested the
effects of the S1P analogue, FTY720, which functionally antagonises
S1PR1/3, and JTE-013, the S1PR2 receptor antagonist on S1P actions
in EVT; only the latter was able to abolish the inhibitory effect of
S1P on trophoblast migration. This effect was independent of
changes in cell number. S1PR2 can couple to Ga12/13, which acti-
vates RhoA and downstream molecules that ultimately lead to
stress fibre formation and reduced motility, or Gai, which links to
another small GTPase, Rac that regulates the cellular cytoskeleton
to promote cell migration. The functional data obtained in this
study indicate that EVT, S1PR2 primarily couples to Ga12/13/RhoA,
despite the demonstrable presence of active Gai. This observation is
in keeping with data from cells engineered to over-express S1PR2
in which S1P-mediated activation of ERK (a downstream marker of
coupling to Gai) was less efficient than in cells expressing S1PR1 or
R3 [30].
RhoA mediates stress fibre formation and focal adhesion
through a phosphorylation cascade beginning with Rho kinase
(ROCK) to impede the activity of cofilin and myosin light-chain
phosphatase and stabilise actin filaments. Cells with strong stress
fibres are generally less motile and stress fibres are known to
inhibit cell motility. Treatment of Swan-71 cells with S1P resulted
in the induction of stress fibres which was blocked by pre-
treatment with the specific Rho kinase inhibitor Y-27632. These
findings are in agreement with those of Lepley et al., who found
that S1P mediated formation of stress fibres and the inhibition of
glioblastoma cell migration was dependent on S1PR2/Rho/ROCK
[31], although studies of CHO cells that over-express S1PR2 suggest
that Rho-kinase-independent mechanisms for S1PR2/Ga12/13/Rho
regulating cell migration [17] also exist.
In addition to inhibiting cell migration by activating Rho and
consequently ROCK, S1P-activated Rho may also attenuate cell
motility by inhibiting the activity of the pro-migratory GTPase Rac
(a downstream mediator of Gai) [17,32,33] through mechanisms
involving stimulation of a GTPase-activating protein (GAP) for Rac
[34]. It is possible that in EVT robust activation of Ga12/13 following
S1P/S1PR2 interactions masks Gai-mediated stimulation of Rac,
thus strategies aimed at enhancing the latter pathway, for example
overexpression of Gai, as demonstrated by Sugimoto et al. [17], or
inhibition/down-regulation of GAPs, might overcome the conse-
quences of S1PR2/Ga12/13 signalling for cell migration.
We found no difference in mRNA expression levels of S1PR1, R2
and R3 in our trophoblast cell models. S1P is reported to have a
similar affinity for each of the S1P receptors R1-R3 [35,36] and we
demonstrated that S1PR1 was capable of responding to the con-
centration of S1P used by assessing the effect of S1P on cAMP
production in the presence of the S1PR1 inhibitor FTY720. None-
theless, S1P inhibited the migration of all of the trophoblast models
investigated, which suggests that S1P preferentially activates sig-
nalling through S1PR2. It is unknown why this occurs in EVT and
other cell types, but it is possible that the S1P receptors are subject
to “biased signalling” inwhich specific receptor conformations, and
the consequent signalling behaviours, are stabilised at the exclu-
sion of other states.
This is the first study to examine the effect of vitamin D on S1P
receptors in trophoblast. Vitamin D insufficiency/deficiency during
pregnancy has been linked to an increased risk of developing pre-
eclampsia [19]. Our key finding is that S1P's inhibitory affect on
trophoblast migration was completely abolished by pre-treatment
of cells with D3 and that this was mediated by down regulation
of S1PR2 mRNA. These observations support those of Kikuta et al.
[25] who found that in both in vitro and in vivo models, D3 sup-
pressed the expression of S1PR2 and consequently alleviated S1P
inhibition of osteoclast precursor monocyte migration. Interest-
ingly Vitamin D and its analogue, BXL-628, have been shown toinhibit themigration of human and rat bladder smoothmuscle cells
by blocking the activation of the RhoA/ROCK signalling pathway
[37]. The authors of this study did not investigate the molecules
upstream of RhoA, however it is tempting to speculate that the
effects of vitamin D were due to down-regulation of S1PR2
expression.
Observational studies in humans suggest that low D3 levels are
associated with a number of pregnancy complications, including
pre-eclampsia [38]. In the UK, all pregnant women are advised to
supplement their diet by taking 400 international units (IU)
vitamin D daily to counter the well-recognised bone defects asso-
ciated with deficiency [39]. Such a dose is reported to raise circu-
lating levels of the D3 precursor, 25-hydroxyvitamin D (25(OH)D),
by 4 ng/ml (10 nM) [40]; it is likely that 1,25D levels are similarly
increased following vitamin D supplementation which, according
to the results of our study, would be sufficient to affect the
expression of S1PR2. It is therefore interesting to note the findings
of a recent systematic review which suggest that daily supple-
mentation with 800-1000IU vitamin D protects against low birth
weight [41]. Moreover, an analysis of over 23,000 nulliparous
women taking part in the Norwegian Mother and Child Cohort
study revealed that supplementary intake of vitamin D conferred a
protective, albeit small, effect against developing pre-eclampsia
and interestingly, supplementation in both early and late preg-
nancy was advantageous [42]. The authors suggest that in early
pregnancy, vitamin D may be an important regulator of genes re-
quires for successful pregnancy whereas later in gestation, it may
influence the maternal immune response to the fetus [42]; our data
suggest that it’s potential to modulate the S1P axis, and therefore
trophoblast migration, should also be considered as a contributory
factor.
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